Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

INTRODUCTION: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Rheumatol Ther
Glavni autori: Nash, Peter, McInnes, Iain B., Mease, Philip J., Thom, Howard, Hunger, Matthias, Karabis, Andreas, Gandhi, Kunal, Mpofu, Shephard, Jugl, Steffen M.
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935619/
https://ncbi.nlm.nih.gov/pubmed/29605841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-018-0106-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items